MXPA03008096A - Metodo para aumentar los niveles de leptina utilizando compuestos de acido nicotinico. - Google Patents
Metodo para aumentar los niveles de leptina utilizando compuestos de acido nicotinico.Info
- Publication number
- MXPA03008096A MXPA03008096A MXPA03008096A MXPA03008096A MXPA03008096A MX PA03008096 A MXPA03008096 A MX PA03008096A MX PA03008096 A MXPA03008096 A MX PA03008096A MX PA03008096 A MXPA03008096 A MX PA03008096A MX PA03008096 A MXPA03008096 A MX PA03008096A
- Authority
- MX
- Mexico
- Prior art keywords
- nicotinic acid
- leptin
- ester
- leptin levels
- medicament
- Prior art date
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 102000016267 Leptin Human genes 0.000 title claims abstract description 59
- 108010092277 Leptin Proteins 0.000 title claims abstract description 59
- 229940039781 leptin Drugs 0.000 title claims abstract description 59
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 40
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 40
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 37
- -1 nicotinic acid ester Chemical class 0.000 claims abstract description 27
- 150000002148 esters Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 101150014691 PPARA gene Proteins 0.000 description 5
- BAWFJGJZGIEFAR-DQQFMEOOSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)O[P@@](O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-DQQFMEOOSA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010029098 Neoplasm skin Diseases 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- LKBWKOLZHMWUGN-UHFFFAOYSA-N 2-dodecylpyridine-3-carboxylic acid Chemical compound CCCCCCCCCCCCC1=NC=CC=C1C(O)=O LKBWKOLZHMWUGN-UHFFFAOYSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 239000000852 hydrogen donor Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 102000005861 leptin receptors Human genes 0.000 description 2
- 108010019813 leptin receptors Proteins 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940081826 myristyl nicotinate Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000008491 skin homeostasis Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 208000036391 Genetic obesity Diseases 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000037493 inherited obesity Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27434901P | 2001-03-08 | 2001-03-08 | |
| PCT/US2002/007256 WO2002072092A1 (en) | 2001-03-08 | 2002-03-08 | Method for increasing leptin levels using nicotinic acid compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03008096A true MXPA03008096A (es) | 2005-10-05 |
Family
ID=23047813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03008096A MXPA03008096A (es) | 2001-03-08 | 2002-03-08 | Metodo para aumentar los niveles de leptina utilizando compuestos de acido nicotinico. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6750234B2 (https=) |
| EP (1) | EP1365762B1 (https=) |
| JP (1) | JP5057353B2 (https=) |
| CN (1) | CN1265792C (https=) |
| AT (1) | ATE409037T1 (https=) |
| CA (1) | CA2437844C (https=) |
| DE (1) | DE60229041D1 (https=) |
| DK (1) | DK1365762T3 (https=) |
| ES (1) | ES2315358T3 (https=) |
| MX (1) | MXPA03008096A (https=) |
| PT (1) | PT1365762E (https=) |
| WO (1) | WO2002072092A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2416788A1 (en) | 2000-07-31 | 2002-02-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds |
| US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
| US6750234B2 (en) * | 2001-03-08 | 2004-06-15 | University Of Kentucky Research Foundation | Methods for increasing leptin levels using nicotinic acid compounds |
| BR0315942A (pt) * | 2002-11-27 | 2005-10-04 | Dmi Biosciences Inc | Tratamento de doenças e condições mediadas pelo aumento de fosforilação |
| US7736636B2 (en) * | 2003-02-12 | 2010-06-15 | Shaker Mousa | Method for treating occlusive vascular diseases & wound healing |
| US9544860B2 (en) | 2003-02-24 | 2017-01-10 | Qualcomm Incorporated | Pilot signals for use in multi-sector cells |
| US7218948B2 (en) | 2003-02-24 | 2007-05-15 | Qualcomm Incorporated | Method of transmitting pilot tones in a multi-sector cell, including null pilot tones, for generating channel quality indicators |
| US8811348B2 (en) | 2003-02-24 | 2014-08-19 | Qualcomm Incorporated | Methods and apparatus for generating, communicating, and/or using information relating to self-noise |
| WO2005013885A2 (en) | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| NZ555079A (en) | 2004-10-14 | 2010-04-30 | Qualcomm Inc | Methods and apparatus for determining, communicating and using information which can be used for interference control purposes |
| US8503938B2 (en) | 2004-10-14 | 2013-08-06 | Qualcomm Incorporated | Methods and apparatus for determining, communicating and using information including loading factors which can be used for interference control purposes |
| JP2006253769A (ja) * | 2005-03-08 | 2006-09-21 | National Institute Of Advanced Industrial & Technology | 情報処理システムおよび方法 |
| EP1898867B1 (en) | 2005-06-24 | 2017-08-09 | Arizona Board of Regents, acting on behalf of the University of Arizona | Method for treating hair growth disorders, such as female pattern alopecia, and compositions useful therefore |
| EP2452686A3 (en) | 2005-08-29 | 2012-09-05 | HealOr Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
| US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| US9191840B2 (en) | 2005-10-14 | 2015-11-17 | Qualcomm Incorporated | Methods and apparatus for determining, communicating and using information which can be used for interference control |
| US8694042B2 (en) | 2005-10-14 | 2014-04-08 | Qualcomm Incorporated | Method and apparatus for determining a base station's transmission power budget |
| US9572179B2 (en) | 2005-12-22 | 2017-02-14 | Qualcomm Incorporated | Methods and apparatus for communicating transmission backlog information |
| US9451491B2 (en) | 2005-12-22 | 2016-09-20 | Qualcomm Incorporated | Methods and apparatus relating to generating and transmitting initial and additional control information report sets in a wireless system |
| US9148795B2 (en) | 2005-12-22 | 2015-09-29 | Qualcomm Incorporated | Methods and apparatus for flexible reporting of control information |
| US9125092B2 (en) | 2005-12-22 | 2015-09-01 | Qualcomm Incorporated | Methods and apparatus for reporting and/or using control information |
| US7801589B2 (en) | 2005-12-22 | 2010-09-21 | Olympus Corporation | In-vivo examination method and in-vivo examination apparatus |
| US9125093B2 (en) | 2005-12-22 | 2015-09-01 | Qualcomm Incorporated | Methods and apparatus related to custom control channel reporting formats |
| US8514771B2 (en) | 2005-12-22 | 2013-08-20 | Qualcomm Incorporated | Methods and apparatus for communicating and/or using transmission power information |
| US9137072B2 (en) | 2005-12-22 | 2015-09-15 | Qualcomm Incorporated | Methods and apparatus for communicating control information |
| US9338767B2 (en) | 2005-12-22 | 2016-05-10 | Qualcomm Incorporated | Methods and apparatus of implementing and/or using a dedicated control channel |
| US8437251B2 (en) | 2005-12-22 | 2013-05-07 | Qualcomm Incorporated | Methods and apparatus for communicating transmission backlog information |
| US9473265B2 (en) | 2005-12-22 | 2016-10-18 | Qualcomm Incorporated | Methods and apparatus for communicating information utilizing a plurality of dictionaries |
| US9119220B2 (en) | 2005-12-22 | 2015-08-25 | Qualcomm Incorporated | Methods and apparatus for communicating backlog related information |
| US20070249360A1 (en) | 2005-12-22 | 2007-10-25 | Arnab Das | Methods and aparatus related to determining, communicating, and/or using delay information in a wireless communications system |
| US20070243882A1 (en) | 2006-04-12 | 2007-10-18 | Qualcomm Incorporated | Method and apparatus for locating a wireless local area network associated with a wireless wide area network |
| WO2008026349A1 (fr) * | 2006-08-31 | 2008-03-06 | Juridical Foundation Osaka Industrial Promotion Organization | Agent thérapeutique destiné au traitement de l'effluvium télogène |
| JP5699414B2 (ja) * | 2007-02-28 | 2015-04-08 | ユニバーシティー オブ ケンタッキー リサーチ ファウンデイション | レチノイン酸療法の効力を妨げることなくレチノイン酸療法の副作用を軽減する方法、および／又は、その効力を改善する方法 |
| EP2523677A2 (en) | 2010-01-11 | 2012-11-21 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
| CN109414424A (zh) * | 2016-04-22 | 2019-03-01 | 无锡杰西医药股份有限公司 | 异硫氰酸酯类化合物的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4505896A (en) * | 1979-04-19 | 1985-03-19 | Elorac, Ltd. | Method of treating acne vulgaris and composition |
| DE3110611A1 (de) * | 1981-03-18 | 1982-10-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | "mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten" |
| GB8330969D0 (en) * | 1983-11-21 | 1983-12-29 | Wellcome Found | Promoting healing |
| DE3570598D1 (en) * | 1984-11-15 | 1989-07-06 | Nitto Denko Corp | Composition for percutaneous administration |
| US4965252A (en) * | 1988-06-28 | 1990-10-23 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination compositions of guar gum and niacin |
| EP0573568B1 (en) * | 1991-03-01 | 2001-01-24 | University Of Florida Research Foundation, Inc. | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| US5240945A (en) * | 1992-02-18 | 1993-08-31 | Warshaw Thelma G | Method and compositions for treating acne |
| US5612382A (en) * | 1994-07-15 | 1997-03-18 | Frances B. Fike | Composition for percutaneous absorption of pharmaceutically active ingredients |
| US5496827A (en) * | 1994-07-15 | 1996-03-05 | Patrick; Jay | Compositions for the transdermal delivery of nutrients |
| AU5524896A (en) * | 1995-03-20 | 1996-10-08 | Institut Pasteur De Lille | Modulators of ob gene and screening methods therefor |
| DK0823897T3 (da) * | 1995-05-01 | 2004-12-06 | Scarista Ltd | Nicotinsyreestere og farmaceutiske præparater indeholdende disse |
| WO1998052927A1 (en) * | 1997-05-19 | 1998-11-26 | Rosemarie Scivoletto | Composition for treating skin conditions |
| WO1999059614A1 (en) * | 1998-05-20 | 1999-11-25 | Yale University | Modulation of angiogenesis and wound healing |
| PT1143954E (pt) * | 1998-12-01 | 2004-12-31 | Univ Kentucky Res Found | Utilizacao de derivados de acido nocotinico para o tratamento de danos no adn em celulas da pele |
| IT1306141B1 (it) * | 1999-05-17 | 2001-05-30 | Giampiero Valletta | Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche. |
| US6326034B1 (en) * | 1999-12-22 | 2001-12-04 | Natural Compounds Ltd | Natural extracted and synthetic antioxidant compositions |
| US6750234B2 (en) * | 2001-03-08 | 2004-06-15 | University Of Kentucky Research Foundation | Methods for increasing leptin levels using nicotinic acid compounds |
-
2002
- 2002-03-08 US US10/094,063 patent/US6750234B2/en not_active Expired - Lifetime
- 2002-03-08 CN CNB028061209A patent/CN1265792C/zh not_active Expired - Fee Related
- 2002-03-08 CA CA002437844A patent/CA2437844C/en not_active Expired - Lifetime
- 2002-03-08 AT AT02721337T patent/ATE409037T1/de active
- 2002-03-08 EP EP02721337A patent/EP1365762B1/en not_active Expired - Lifetime
- 2002-03-08 DK DK02721337T patent/DK1365762T3/da active
- 2002-03-08 DE DE60229041T patent/DE60229041D1/de not_active Expired - Lifetime
- 2002-03-08 JP JP2002571051A patent/JP5057353B2/ja not_active Expired - Fee Related
- 2002-03-08 PT PT02721337T patent/PT1365762E/pt unknown
- 2002-03-08 ES ES02721337T patent/ES2315358T3/es not_active Expired - Lifetime
- 2002-03-08 MX MXPA03008096A patent/MXPA03008096A/es active IP Right Grant
- 2002-03-08 WO PCT/US2002/007256 patent/WO2002072092A1/en not_active Ceased
-
2004
- 2004-04-14 US US10/825,405 patent/US20040198776A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040198776A1 (en) | 2004-10-07 |
| CN1265792C (zh) | 2006-07-26 |
| WO2002072092A1 (en) | 2002-09-19 |
| PT1365762E (pt) | 2008-11-27 |
| EP1365762A4 (en) | 2005-05-25 |
| EP1365762B1 (en) | 2008-09-24 |
| DK1365762T3 (da) | 2008-11-17 |
| CA2437844A1 (en) | 2002-09-19 |
| JP5057353B2 (ja) | 2012-10-24 |
| ES2315358T3 (es) | 2009-04-01 |
| HK1065941A1 (en) | 2005-03-11 |
| JP2004519488A (ja) | 2004-07-02 |
| ATE409037T1 (de) | 2008-10-15 |
| US6750234B2 (en) | 2004-06-15 |
| DE60229041D1 (de) | 2008-11-06 |
| CN1496260A (zh) | 2004-05-12 |
| CA2437844C (en) | 2007-05-15 |
| EP1365762A1 (en) | 2003-12-03 |
| US20020128298A1 (en) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2437844C (en) | Method for increasing leptin levels using nicotinic acid compounds | |
| Soler et al. | Polyamines regulate expression of the neoplastic phenotype in mouse skin | |
| Bivalacqua et al. | Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats | |
| JP2020075936A (ja) | 寿命を拡大させ、かつ加齢関連疾患の発症を遅らせるための方法 | |
| US5955059A (en) | Use of locally applied DNA fragments | |
| Murata et al. | Improved tumor response by combining radiation and the vascular-damaging drug 5, 6-dimethylxanthenone-4-acetic acid | |
| Bertsch et al. | Effect of mechanical stimulation on cell proliferation in mouse epidermis and on growth regulation by endogenous factors (chalones) | |
| Liversidge et al. | Rat retinal pigment epithelial cells express an inducible form of nitric oxide synthase and produce nitric oxide in response to inflammatory cytokines and activated T cells | |
| CN101642458A (zh) | 包含皮质类固醇和Hedgehog/平滑信号传导抑制剂的药物组合物 | |
| CA2883348C (en) | Composition comprising dihydroquercetin, a-tocopherol and bisabolol | |
| CA2280770C (en) | Gene therapy for alleviating erectile dysfunction | |
| AU5300596A (en) | Treatment of cytokine growth factor caused disorders | |
| US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
| Mikkonen et al. | Effect of thyroid hormones, somatotrophin, insulin and corticosteroids on synthesis of collagen in granulation tissue both in vivo and in vitro | |
| Uitto et al. | Fibrotic skin diseases: clinical presentations, etiologic considerations, and treatment options | |
| US7026319B1 (en) | Use of vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation | |
| EP1427383B1 (en) | Compositions and methods relating to prevention of chemotherapy-induced alopecia | |
| Braunschweiger et al. | Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1α | |
| PEDEN et al. | Anabolic effect of a new synthetic steroid on nitrogen metabolism after operation | |
| US20070042976A1 (en) | Method of treating cosmetic and dermatologic conditions by a demethylating agent | |
| US20230321004A1 (en) | Methods and Compositions for Treating Melanoma and Non-Melanoma Skin Cancers | |
| WO2004000245A1 (ja) | 細胞への塩基性アミノ酸取り込み促進剤および化粧料もしくは医薬組成物 | |
| HK1065941B (en) | Use of a nicotinic acid alkyl ester containing an alkyl chain from 8 to 22 carbon atoms for the preparation of a medicament for increasing leptin levels in a subject | |
| Friedman et al. | Ca antagonist verapamil and tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) induce chromosomal aberrations in human lymphocytes | |
| Werth et al. | 1081 BIIB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |